Oxford Biomedica Logo
Scientist microscope

Oxford BioMedica Plc - Research and Development Day - 01/07/2010

2010/OB/16

Oxford, UK – 1 July 2010: Oxford BioMedica (LSE: OXB), a leading gene therapy company, will hold an R&D day for analysts and investors today in London.

The meeting will focus on the Company’s Parkinson’s disease and ocular disorders programmes and the applicability of its LentiVector® technology. Presentations will be made by members of Oxford BioMedica’s Senior Management Team and also by Key Opinion Leaders associated with the Company, namely Professor Stephane Palfi, Principal Investigator of Oxford BioMedica’s ProSavin trial, and Peter Francis, Associate Professor, Co-Director, Oregon Retinal Degeneration Center.
A copy of the presentation will be available following the meeting from Oxford BioMedica’s website: http://www.oxfordbiomedica.co.uk. The company will not be disclosing any new material information.
- Ends -

Notes to editors

1.

Oxford BioMedica plc
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company’s technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline. Partners include sanofi-aventis, Sigma-Aldrich and Wyeth. Technology licensees include Biogen-Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk
 
For further information please contact:
Oxford BioMedica plc
Lara Mott, Head of Corporate Communications		 Tel: +44 (0)1865 783 000
JPMorgan Cazenove Limited
James Mitford/Gina Gibson		 Tel: +44 (0)20 7588 2828
M: Communications Media/Financial Enquiries
Emma Thompson/Rob Newman/Ben Simons		 Tel: +44 (0)20 7920 2345
US Enquiries
Thomas Fechtner
The Trout Group LLC		 Tel: +1 646 378 2900